KNOXVILLE, TN / ACCESSWIRE / August 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a live conference
call and webcast to discuss the results of the second quarter 2016, to be held Wednesday, August 10, 2016 at 4:00 PM Eastern
Time.
To participate in this event, dial 877-407-4019 domestically, or 201-689-8337 internationally, approximately 5 to 10 minutes
before the beginning of the call. Additionally, you can listen to the event online at
www.investorcalendar.com/IC/CEPage.asp?ID=175162 as well as via the Provectus Biopharmaceuticals website
(www.provectusbio.com).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or
www.provectusbio.com.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer.
Provectus' investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The
Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry,
www.clinicaltrials.gov. ;For additional information about Provectus, please visit the Company's website at www.provectusbio.com or
contact Porter, LeVay & Rose, Inc.
SOURCE: Investor Calendar
